A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Fabry Disease
Interventions
DRUG

migalastat HCl 150 mg

migalastat HCl 150 mg capsule

Trial Locations (15)

3050

RECRUITING

Royal Melbourne Hospital, Parkville

6000

RECRUITING

Royal Perth Hospital, Perth

22030

RECRUITING

Lysosomal and Rare Disorders Research and Treatment Center, Inc, Fairfax

28007

RECRUITING

Hospital General Universitario Gregorio Marañon, Madrid

30322

RECRUITING

Emory University, Atlanta

41013

WITHDRAWN

Hospital Universitario Reina Sofia, Córdoba

44195

RECRUITING

The Cleveland Clinic, Cleveland

75020

WITHDRAWN

Internal Medicine Unit Croix Saint Simon Hospital, Paris

75235

WITHDRAWN

Renal Disease Research Institute, Dallas

565-0871

RECRUITING

Osaka University Hospital, Suita

420-8527

RECRUITING

Shizuoka General Hospital, Shizuoka

3041-801

RECRUITING

Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra

08907

RECRUITING

Hospital Universitari(o) de Bellvitge (HUB) Feixa Llarga, Barcelona

03600

RECRUITING

Hospital General Universitario de Elda, Elda

M6 8HD

RECRUITING

Salford Royal Hospital, Salford

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY